This website uses cookies. By continuing to access the site you are agreeing to their use. Learn more about cookies.

Select country
  • language Clinigen France
  • language Clinigen Germany
  • About Clinigen
    • About us
    • History
    • Responsible business
    • Operational excellence
    • Our brands
  • Global offices
    • Australia & New Zealand
    • Japan
    • Singapore
    • South Africa
    • United Kingdom
    • United States
  • Careers
    • Careers overview
    • Apply Online
    • Frequently Asked Questions
    • Privacy Notice - Applicants
  • Investors
    • At a Glance
    • Financial Highlights
    • Investment Case
      • Business Model
      • Our Track Record
      • Market Overview
      • Strategy
      • Our Businesses
    • Share Tools
    • Results, Reports and Presentations
    • Quantum Archive
    • Financial Calendar
    • Press Releases
      • Press Releases
      • Regulatory News
      • Email Alerts
    • Shareholder Services
      • AGM
      • Registrar Services
      • Major Shareholders
      • Advisor Contacts
      • Analyst Coverage
    • AIM Rule 26
    • Corporate Governance
      • Corporate Governance Statement
      • Board of Directors
      • Tax Strategy
  • Newsroom
    • Video Library
    • Press Releases
Clinigen-Logo.png
  • Mission
  • How we can help
    Pharmaceutical & Biotech Companies
    Healthcare Professionals
    Patient Groups
    Patients
  • Medicines & Services
    Commercial Medicines >
    • CARDIOXANE®
    • ETHYOL®
    • FOSCAVIR®
    • SAVENE® (Non US)
    • TOTECT® (US only)
    • Partnering with Clinigen
    Unlicensed Medicines >
    • Policy Development
    • Asset Strategy
    • Early Access
    • Real World Evidence
    • Post-Trial Access
    • Phased Launch and Non-Launch Markets
    • Medicine Shortages
    • Market Withdrawal/ Discontinuations
    • Consulting Services
    Clinical Trial Services >
    • Comparator Sourcing and Ancillary Supply
    • Direct-to-site
    • Demand Driven Labelling & Distribution
    • Investigator Initiated Trials
    • Technical Consultancy

    Cliniport Medicine Finder

    Cliniport medicine finder provides access to 10,000 licensed and unlicensed products.

    About Cliniport
  • Insights
Cliniport medicine finder
About Cliniport
Login
Get in touch
Get in touch
  • Mission
  • How we can help
    How we can help
    • Pharmaceutical & Biotech Companies
    • Healthcare Professionals
    • Patient Groups
    • Patients
  • Medicines & Services
    Medicines & Services
    • Commercial Medicines >
      Commercial Medicines >

      Commercial Medicines >

      • CARDIOXANE®
      • ETHYOL®
      • FOSCAVIR®
      • SAVENE® (Non US)
      • TOTECT® (US only)
      • Partnering with Clinigen
    • Unlicensed Medicines >
      Unlicensed Medicines >

      Unlicensed Medicines >

      • Policy Development
      • Asset Strategy
      • Early Access
      • Real World Evidence
      • Post-Trial Access
      • Phased Launch and Non-Launch Markets
      • Medicine Shortages
      • Market Withdrawal/ Discontinuations
      • Consulting Services
    • Clinical Trial Services >
      Clinical Trial Services >

      Clinical Trial Services >

      • Comparator Sourcing and Ancillary Supply
      • Direct-to-site
      • Demand Driven Labelling & Distribution
      • Investigator Initiated Trials
      • Technical Consultancy
  • Insights
  • About Clinigen
    About Clinigen

    About Clinigen

    • About us
    • History
    • Responsible business
    • Operational excellence
    • Our brands
  • Global offices
    Global offices

    Global offices

    • Australia & New Zealand
    • Japan
    • Singapore
    • South Africa
    • United Kingdom
    • United States
  • Careers
    Careers

    Careers

    • Careers overview
    • Apply Online
    • Frequently Asked Questions
    • Privacy Notice - Applicants
  • Investors
    Investors

    Investors

    • At a Glance
    • Financial Highlights
    • Investment Case
      Investment Case

      Investment Case

      • Business Model
      • Our Track Record
      • Market Overview
      • Strategy
      • Our Businesses
    • Share Tools
    • Results, Reports and Presentations
    • Quantum Archive
    • Financial Calendar
    • Press Releases
      Press Releases

      Press Releases

      • Press Releases
      • Regulatory News
      • Email Alerts
    • Shareholder Services
      Shareholder Services

      Shareholder Services

      • AGM
      • Registrar Services
      • Major Shareholders
      • Advisor Contacts
      • Analyst Coverage
    • AIM Rule 26
    • Corporate Governance
      Corporate Governance

      Corporate Governance

      • Corporate Governance Statement
      • Board of Directors
      • Tax Strategy
  • Newsroom
    Newsroom

    Newsroom

    • Video Library
    • Press Releases
Cliniport
  • About Cliniport
  • Login
Select Country
  • Clinigen France
  • Clinigen Germany

Press Releases

  • At a Glance
  • Financial Highlights
  • Investment Case
    • Business Model
    • Our Track Record
    • Market Overview
    • Strategy
    • Our Businesses
  • Share Tools
  • Results, Reports and Presentations
  • Quantum Archive
  • Financial Calendar
  • Press Releases
    • Press Releases
    • Regulatory News
    • Email Alerts
  • Shareholder Services
    • AGM
    • Registrar Services
    • Major Shareholders
    • Advisor Contacts
    • Analyst Coverage
  • AIM Rule 26
  • Corporate Governance
    • Corporate Governance Statement
    • Board of Directors
    • Tax Strategy
  • 2019
  • 2018
  • 2017
  • Archive
More
Filter by
  • 04 Mar 2019

    Clinigen and Eiger BioPharmaceuticals launch worldwide Managed Access Program for lonafarnib for patients with Progeria and Progeroid Laminopathies
    Related materials
    PDF (293.01KB)
  • 27 Feb 2019

    Half Year Results for the Six Months Ended 31 December 2018
    Related materials
    PDF (1.08MB) Presentation Webcast
  • 22 Feb 2019

    Clinigen granted additional indication for Glycopyrronium Bromide to treat paediatric and adolescent severe hypersalivation
    Related materials
    PDF (198.28KB)
  • 13 Feb 2019

    Clinigen to acquire US rights to Proleukin
    Related materials
    PDF (358.42KB)
  • 12 Feb 2019

    Notification of half year results date
  • 05 Feb 2019

    Nick Keher appointed CFO
    Related materials
    PDF (194.03KB)
  • 15 Jan 2019

    Half Year trading update
    Related materials
    PDF (434.62KB)
  • 10 Jan 2019

    Clinigen extends exclusive European clinical trial sourcing and supply agreement with Accord Healthcare

Our global offices
  • Australia & New Zealand
  • Japan
  • Singapore
  • South Africa
  • United Kingdom
  • United States
Site
tools
  • AE Reporting
  • Medical enquiries
  • Terms of use
  • Cookies
  • Privacy policy
  • UK Gender Pay Gap Report
  • Modern Slavery Statement
  • Access Online
  • Sitemap
  • Consumer Information Obligations
Access cliniport

Cliniport medicine finder provides Healthcare Professionals with safe and secure access to 10,000 licensed and unlicensed products.

Log In About Cliniport
Subscribe to our email alerts
  • Twitter
  • Vimeo
  • Linkedin
© Copyright 2019 Clinigen Group plc. By Emperor